|
Amputated structure (morphologic abnormality)
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
SGLT2 inhibitor treatment was also associated with similar relative risks in women and men for the safety outcomes of amputation, fracture, genital infection and urinary tract infection (all P for interaction ≥.17).
|
31486272 |
2020 |
|
Amputated structure (morphologic abnormality)
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
To examine whether sodium-glucose co-transporter-2 (SGLT2) inhibitors are associated with a higher risk of lower-extremity amputation than dipeptidyl-peptidase-4 (DPP-4) inhibitors and sulphonylureas.
|
30697897 |
2019 |
|
Amputated structure (morphologic abnormality)
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Additionally, SGLT2 inhibitors were associated with lower risk of hospitalization because of heart failure compared to both sulfonylureas and DPP-4 inhibitors, as well as lower risk of lower extremity amputation compared to sulfonylureas.
|
30039524 |
2019 |
|
Amputated structure (morphologic abnormality)
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Care is required when prescribing the SGLT2 inhibitor class of medications to people with foot vascular issues or prior amputation, and to insulin users in regard of ketoacidosis.
|
30607467 |
2019 |
|
Amputated structure (morphologic abnormality)
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
MH-OR for amputation in the three cardiovascular safety trials with SGLT-2 inhibitors was 1.22 [0.59-2.52].
|
31150722 |
2019 |
|
Amputated structure (morphologic abnormality)
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
In this article, our main aim is to review the available evidence in preclinical and clinical studies regarding SGLT-2 inhibitors and PAD events, the possible mechanisms related to increased risk of amputation, to evaluate whether it is a class effect or individual drug effect, and most importantly, implications for their continued use as antidiabetic agents.
|
30195639 |
2019 |
|
Amputated structure (morphologic abnormality)
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
The objective of this study was to evaluate the safety risks, specifically the risks of amputation and bone fracture, associated with sodium-glucose cotransporter 2 (SGLT2) inhibitors by using the difference in restricted mean survival time (RMST), an alternative measure to the hazard ratio.
|
30506378 |
2019 |
|
Amputated structure (morphologic abnormality)
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Empagliflozin is generally well tolerated as monotherapy or as add-on therapy and, unlike canagliflozin (the only other SGLT2 inhibitor that has so far shown CV and renal benefits), it has not been associated with an increased risk of amputation or bone fractures.
|
29946963 |
2018 |
|
Amputated structure (morphologic abnormality)
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
SGLT2 inhibitors were also associated with infections, volume depletion effects and amputation.
|
29604389 |
2018 |
|
Amputated structure (morphologic abnormality)
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
In this analysis of nationwide registers from two countries, use of SGLT2 inhibitors, as compared with GLP1 receptor agonists, was associated with an increased risk of lower limb amputation and diabetic ketoacidosis, but not with other serious adverse events of current concern.
|
30429124 |
2018 |
|
Amputated structure (morphologic abnormality)
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real-world meta-analysis of 4 observational databases (OBSERVE-4D).
|
29938883 |
2018 |
|
Amputated structure (morphologic abnormality)
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Use of SGLT-2 inhibitors may be associated with increased risk of amputation compared with some oral treatments for type 2 diabetes.
|
30105373 |
2018 |
|
Amputated structure (morphologic abnormality)
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The incidence rates of BKLE amputation were 1.18 and 1.12 events per 1000 person-years with canagliflozin and non-SGLT2 inhibitor AHAs, respectively; the hazard ratio was 0.98 (95% confidence interval 0.68-1.41; P = .92, calibrated P = .95).
|
28898514 |
2018 |
|
Amputated structure (morphologic abnormality)
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Among the 8 293 886 reports available between January 2013 and December 2017, we identified 79 reports of lower-limb amputation that were associated with SGLT-2 inhibitors.
|
29430814 |
2018 |
|
Amputated structure (morphologic abnormality)
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Despite a significant reduction in major adverse CV events with SGLT2 inhibitor treatment, however, an unexpected increased risk of amputation was observed in the CANVAS program and the subsequent pharmacovigilance analysis.
|
29025400 |
2017 |